Table 3.
Markers of oxidative stress, inflammation, and NO metabolites of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT
| T2DM-SCT | T2DM | SCT | CONT | |
|---|---|---|---|---|
| AOPP (µmol/L) | 122.9 ± 47.1** | 88.1 ± 32.6 | 93.6 ± 66.0 | 63.1 ± 20.3 |
| MDA (µmol/L) | 37.3 ± 16.7* | 30.3 ± 16.0 | 26.8 ± 7.1 | 22.9 ± 11.5 |
| Nitrotyrosine (µmol/L) | 1.8 ± 1.2***,† | 1.1 ± 0.6 | 0.8 ± 0.5 | 0.6 ± 0.5 |
| AGEs (µg/mL) | 2.7 ± 1.0***,†††,### | 1.5 ± 0.9*,† | 0.7 ± 0.8 | 0.5 ± 0.4 |
| FRAP (µmol/L | 449.2 ± 144.4 | 555.3 ± 127.6 | 568.5 ± 243.3 | 627.5 ± 269.0 |
| sVCAM-1 (ng/mL) | 1,079.4 ± 657.2 | 826.2 ± 179.1 | 897.1 ± 309.3 | 724.0 ± 178.8 |
| IL-1β (ng/mL) | 7.2 ± 3.0***,†††,### | 3.8 ± 2.1*,† | 1.9 ± 1.0 | 1.7 ± 0.9 |
| NOx (µmol/L) | 17.8 ± 5.9 | 21.2 ± 11.0 | 23.4 ± 9.5 | 21.9 ± 4.4 |
Data are means ± SD.
*Different from CONT, P < 0.05.
**P < 0.01.
***P < 0.001.
†Different from SCT, P < 0.05.
†††P < 0.001.
###Different from T2DM, P < 0.001.